Carbapenem-resistant pseudomonas aeruginosa at us emerging infections program sites, 2015
Department
Pathology
Document Type
Article
Publication Title
Emerging Infectious Diseases
Abstract
Pseudomonas aeruginosa is intrinsically resistant to many antimicrobial drugs, making carbapenems crucial in clinical management. During July–October 2015 in the United States, we piloted laboratory-based surveillance for carbapenem- resistant P. aeruginosa (CRPA) at sentinel facilities in Georgia, New Mexico, Oregon, and Tennessee, and population-based surveillance in Monroe County, NY. An incident case was the first P. aeruginosa isolate resistant to antipseudomonal carbapenems from a patient in a 30-day period from any source except the nares, rectum or perirectal area, or feces. We found 294 incident cases among 274 patients. Cases were most commonly identified from respiratory sites (120/294; 40.8%) and urine (111/294; 37.8%); most (223/280; 79.6%) occurred in patients with healthcare
First Page
1281
Last Page
1288
DOI
10.3201/eid2507.181200
Volume
25
Issue
7
Publication Date
7-1-2019
Recommended Citation
Walters, M., Grass, J., Bulens, S., Hancock, E., Phipps, E., Muleta, D., Mounsey, J., Kainer, M., Concannon, C., Dumyati, G., Bower, C., Jacob, J., Cassidy, P., Beldavs, Z., Culbreath, K., Phillips., W., Hardy, D., Vargas, R. L., Oethinger, M., Ansari, U., Stanton, R., Albrecht, V., Halpin, A., Karlsson, M., Rasheed, J., & Kallen, A. (2019). Carbapenem-resistant pseudomonas aeruginosa at us emerging infections program sites, 2015. Emerging Infectious Diseases, 25 (7), 1281-1288. https://doi.org/10.3201/eid2507.181200